摘要
目的 :探讨干扰素 α(赛若金 )治疗慢性乙型肝炎 (乙肝 )疗效与机体免疫状态的关系。方法 :采用抗体致敏的红细胞花环试验及双抗体夹心酶联免疫吸附测定 ( ELISA)大剂量干扰素α治疗前后乙肝患者 T淋巴细胞亚群 CD4+ 、CD8+ 及 CD4+ /CD8+ 、IL - 1 0、IL- 1 2、TNF-α含量。结果 :干扰素 α治疗前 T淋巴细胞亚群 CD4+、CD8+、CD4+ /CD8+比值及 IL- 1 0、IL- 1 2和 TNF- α含量分别为 ( 39.91± 4.5 2 ) %、( 34.1 3± 4.2 4 ) %、( 1 .1 3± 0 .1 2 ) %及 ( 30 .61± 1 1 .2 1 ) pg· L-1 、( 5 8.1 2± 1 3.5 2 ) pg· L-1 和 ( 2 65 .83± 60 .63) pg· L-1 ,治疗 6个月后治疗有效组分别为 ( 4 3.1 2±4.31 ) %、( 30 .81± 5 .1 3) %、( 1 .41± 0 .1 1 ) %及 ( 1 6.5 1± 8.63) pg·L-1 、( 92 .93± 2 1 .5 2 ) pg·L-1 、( 1 2 6.92± 5 3.83) pg·L-1。结论 :大剂量干扰素 α治疗后慢性乙型肝炎患者抗病毒免疫状态明显增强。
Objective: To observe T lymphocyte subsets, IL 10, IL 12 and TNF α level changes in peripheral blood of patients with chronic hepatitis B treated by interferon α(sinogen). Methods: T lymphocyte subsets, IL 10 and IL 12 changes were respectively detected by double sandwich and erythrocyte garland test. Results: CD 4 +,CD 8 + and CD 4 +/CD 8 + ratio and IL 10, IL 12 and TNF α levels were (39.91± 4.52)%,(34.13±4.24)%,(1.13±0.12)%,(30.61±11.21)pg·L -1 ,(58.12± 13.52)pg·L -1 and(265.83±60.63)pg·L -1 before treatment and(43.12±4.31)%,(30.81±5.13)%,(1.41± 0.11)%, (16.51± 8.63)pg·L -1 ,(92.93±21.52)pg·L -1 ,(126.92±53.83)pg·L -1 after treatment, respectively. Conclusion: The CD 4 +,CD 8 +,CD 4 +/CD 8 + ratio and IL 12 level are increased,respectively, and CD 8 +,IL 10, and TNF α levels are lowered and antiviral immune state of patients is enhanced after treatment in responder group.
出处
《吉林大学学报（医学版）》
CAS
CSCD
北大核心
2003年第6期803-805,共3页
Journal of Jilin University：Medicine Edition
基金
吉林省计委科技攻关课题资助项目 (2 0 0 1 1 1 1 5 )
关键词
乙型肝炎
慢性
治疗
干扰素Α
T淋巴细胞亚群
细胞因子类
Hepatitis B,Chronic/therapy
Interferon alpha/therapeutic use
T lymphocyte subsets
Cytokines
